---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059093"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:04:07.465243+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology Q1 net loss narrows to $3.3M; PYX-201 data on track for fall 2024

## Summary
- Revenue of $16.1M from Novartis royalty settlement; net loss $3.3M ($0.06/sh) vs $19.2M ($0.54/sh) YoY.
- Cash & investments $158.5M; runway into 2H 2026; raised ~$60.8M via ATM, private placement, and Novartis deal.
- PYX-201 Phase 1: 42 patients dosed; 16 more planned; results including efficacy expected fall 2024.
- PYX-106 Phase 1: 24 subjects dosed; preliminary data anticipated in 2H 2024.
- Appointed Stephen Worsley as Senior Vice President, Chief Business Officer.

## SEC filing metadata
- accession: 0000950170-24-059093
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017024059093/0000950170-24-059093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017024059093/pyxs-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059093
- JSON: https://secwatch.observer/filing/0000950170-24-059093.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059093.txt

## Key facts
- Earnings Releases
  Pyxis Oncology, Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 14, 2024, Pyxis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024 and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000095017024059093/0000950170-24-059093-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.